Abstract
The article provides an overview of programs, plans, tools of scientific and technological, innovation and industrial policy aimed at creating and producing new drugs in China; it is substantiated that the Chinese government uses an integrated approach in the implementation of mechanisms to protect and strengthen the pharmaceutical industry. It is demonstrated that the Chinese government provides business support in the form of subsidies, tax incentives, the creation of special zones for the development of high-tech industries, and helps to attract foreign direct investment in contract manufacturing and research and development, accompanied by technology transfer; through the public procurement system, a program for the development of endogenous innovations is implemented through the provision of price preferences, and advanced foreign technologies are involved. State support contributed to an increase in the level of localization of production and an increase in the number of jobs, an increase in the added value of production and the competitiveness of the pharmaceutical industry, the formation of scientific and technical competencies and the development of technologies, the creation of objects of intellectual property rights. The Chinese model of investment and innovative development, relying on the use of external technological, production, human resources, has made it possible to form a high-tech pharmaceutical sector capable of producing endogenous innovations. Given the objectives of the policy documents, Chinese enterprises are encouraged to invest in other countries in the interests of the development of Chinese pharmaceuticals.
Highlights
According to the updated forecast of the International Monetary Fund, the fall of the global economy in 2020 as a result of the COVID-19 pandemic may be 4.9 % [1], will have significant negative socio-economic consequences for all countries, worse than from the global financial crisis of 2008
The above and other works are mainly a generalization of the approaches used by the Chinese government, ignoring the details of the basic conditions of the program documents, which are aimed at building national potential, and for this they orient Chinese companies to actively use foreign resources
Materials and methods The theoretical and methodological basis for writing the article was scientific concepts and theoretical developments on the development of the pharmaceutical industry; regulations, targeted programs and plans of the Chinese government in science and technology, innovation, finance, investment, taxation, staffing, public procurement, which contributed to the development of the pharmaceutical industry
Summary
According to the updated forecast of the International Monetary Fund, the fall of the global economy in 2020 as a result of the COVID-19 pandemic may be 4.9 % [1], will have significant negative socio-economic consequences for all countries, worse than from the global financial crisis of 2008. Given the constant increase in technological innovations, the process of overtaking world leaders by Chinese manufacturers requires an increase in the number of networks and (2020), «EUREKA: Social and Humanities» Number 4 a more complex organizational structure, goes beyond the national innovation system [7, 8]. This process of follow-up occurs in four stages: (1) pure imitation (2) innovative imitation (3) imitative innovation and (4) endogenous innovation. The above and other works are mainly a generalization of the approaches used by the Chinese government, ignoring the details of the basic conditions of the program documents, which are aimed at building national potential, and for this they orient Chinese companies to actively use foreign resources
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
